Business
Silo Pharma's PTSD Candidate SPC-15 Achieves Positive Safety Milestone, Paving Way for Accelerated Clinical Trials Under 505(b)(2) Pathway
SPC-15’s intranasal spray formulation meets safety standards for clinical trial developmen...
About this update from Silo Wellness Inc
[{"type":"text","content":"Silo Pharma’s PTSD Candidate SPC-15 Achieves Positive Safety Milestone, Paving Way for Accelerated Clinical Trials Under 505(b)(2) Pathway\n\n\n\n\n\n SPC-15’s intranasal spray formulation meets safety standards for clinical trial development\n \n\n\n\n SARASOTA, FL, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced positive bioanalytical and safety/toxicology results for its U.S. Food and Drug Administration (FDA)-requested 7-day large animal safety study of its lead asset SPC-15.\n \n\n Silo CEO Eric Weisblum commented, “Overall, we believe the positive results of this study confirm that SPC-15’s formulation and spray profile meets the safety standards for clinical trials. While the safety of the oral counterpart to SPC-15 is well documented, our challenge was to develop a viable intranasal therapeutic dose that meets the same safety standards while offering distinct advantages over oral delivery. So far, we believe our intranasal nose-to-brain formulation has met that challenge and supports our potential to bring a safe, easily administered, and rapidly absorbed PTSD therapeutic to market.”\n \n\n The preclinical study compared the safety and overall exposure of the SPC-15 intranasal spray formulation (intended for clinical use) to oral drug administration. Data showed that SPC-15, administered at clinical-representative doses, demonstrated local and systemic safety with no toxicities identified. The study also showed that systemic exposure of intranasal SPC-15 administered at the anticipated therapeutic range is comparable to standard oral administration, which we believe validates the drug’s potential as a targeted intranasal therapeutic for PTSD and stress-induced anxiety that has a potentially greater safety profile.\n \n\n In our opinion, the study data further supports Silo’s planned 505(b)(2) regulatory strategy for its SPC-15 program. This regulatory route allows companies to utilize previously established safety and efficacy data (from approved drugs) to potentially streamline the FDA drug approval process and reduce drug development costs.\n \n\n Silo is currently conducting an IND-enabling GLP (Good L...